Level- Data

Adverse effects

Last updated: 2022 Aug 26

Total hit(s): 34

Select item(s)	Key Findings	Comments (You can add your comments too!)	Original Article (hover to see details)

In total, 868 patients were evaluated for safety (430 in the sotrovimab group and 438 in the placebo group). Patients in the sotrovimab group reported 17% of adverse events, whereas those in the placebo group reported 19%; major adverse events were less likely with sotrovimab than with placebo (in 2% and 6% of the patients, respectively).

✍

34706189
(N Engl J Med)

PMID	34706189 Date of Publishing: 2021 Nov 18
Title	Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
Author(s) name	Gupta A, Gonzalez-Rojas Y et al.
Journal	N Engl J Med
Impact factor	37.91 Citation count: 135
Date of Entry	2022 Aug 26

NLM format

Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, Sarkis E, Solis J, Zheng H, Scott N, Cathcart AL, Hebner CM, Sager J, Mogalian E, Tipple C, Peppercorn A, Alexander E, Pang PS, Free A, Brinson C, Aldinger M, Shapiro AE; COMET-ICE Investigators. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med. 2021 Nov 18;385(21):1941-1950. PMID:34706189

Secondary infections were experienced by 33 patients (21.9%) in the dexamethasone group compared to 43 patients (29.1%) in the standard care group. In addition, 47 patients (31.1%) compared to 42 patients (28.3%) required insulin for glucose control, and 5 patients (3.3%) compared to 9 patients (6.1%) experienced other serious adverse events.

✍

32876695
(JAMA)

PMID	32876695 Date of Publishing: 2020 Oct 6
Title	Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial
Author(s) name	Tomazini BM, Maia IS et al.
Journal	JAMA
Impact factor	14.78 Citation count: 448
Date of Entry	2022 Aug 26

NLM format

Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, Avezum A, Lopes RD, Bueno FR, Silva MVAO, Baldassare FP, Costa ELV, Moura RAB, Honorato MO, Costa AN, Damiani LP, Lisboa T, Kawano-Dourado L, Zampieri FG, Olivato GB, Righy C, Amendola CP, Roepke RML, Freitas DHM, Forte DN, Freitas FGR, Fernandes CCF, Melro LMG, Junior GFS, Morais DC, Zung S, Machado FR, Azevedo LCP; COALITION COVID-19 Brazil III Investigators. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020 Oct 6;324(13):1307-1316. PMID:32876695

Two (13%) of 16 individuals getting conventional care and four (14%) of 29 patients receiving high-dose anakinra experienced bacteremia. Inflammatory relapses did not occur once anakinra was stopped.

✍

32501454
(Lancet Rheumatol)

PMID	32501454 Date of Publishing: 2020 Jun
Title	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
Author(s) name	Cavalli G, De Luca G et al.
Journal	Lancet Rheumatol
Impact factor	- n/a - Citation count: 473
Date of Entry	2022 Aug 26

NLM format

Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, Oltolini C, Castiglioni B, Tassan Din C, Boffini N, Tomelleri A, Farina N, Ruggeri A, Rovere-Querini P, Di Lucca G, Martinenghi S, Scotti R, Tresoldi M, Ciceri F, Landoni G, Zangrillo A, Scarpellini P, Dagna L. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020 Jun;2(6):e325-e331. PMID:32501454

Serious adverse events were reported in 8 (25%) of the tocilizumab group's patients and in 9 (27%) of the group receiving standard care. Both groups experienced a similar level of infection and pulmonary thrombosis. 13% of tocilizumab patients and 12% of patients receiving conventional care had bacterial or fungal infections, respectively.

✍

32482597
(Eur J Intern Med)

PMID	32482597 Date of Publishing: 2020 Jun
Title	Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study
Author(s) name	Campochiaro C, Della-Torre E et al.
Journal	Eur J Intern Med
Impact factor	3.05 Citation count: 208
Date of Entry	2022 Aug 26

NLM format
Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M, Boffini N, Tomelleri A, Baldissera E, Rovere-Querini P, Ruggeri A, Monti G, De Cobelli F, Zangrillo A, Tresoldi M, Castagna A, Dagna L; TOCI-RAF Study Group. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020 Jun;76:43-49. PMID:32482597

None of the participants who were administered molnupiravir faced any serious adverse effects. All of the participants who had been administered molnupiravir faced mild adverse effects.

✍

34450619
(J Antimicrob Chemother)

PMID	34450619 Date of Publishing: 2021 Aug 27
Title	Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Author(s) name	Khoo SH, Fitzgerald R et al.
Journal	J Antimicrob Chemother
Impact factor	4.94 Citation count: 16
Date of Entry	2022 May 14

NLM format

Khoo SH, Fitzgerald R, Fletcher T, Ewings S, Jaki T, Lyon R, Downs N, Walker L, Tansley-Hancock O, Greenhalf W, Woods C, Reynolds H, Marwood E, Mozgunov P, Adams E, Bullock K, Holman W, Bula MD, Gibney JL, Saunders G, Corkhill A, Hale C, Thorne K, Chiong J, Condie S, Pertinez H, Painter W, Wrixon E, Johnson L, Yeats S, Mallard K, Radford M, Fines K, Shaw V, Owen A, Lalloo DG, Jacobs M, Griffiths G. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. J Antimicrob Chemother. 2021 Nov 12;76(12):3286-3295. PMID:34450619

Mild (grade 2) side effects occured in 4 of 4, 4 of 4 and 1 of 4 of the participants receiving 300, 600 and 800mg molnupiravir, respectively. 5 of 6 controls also showed mild side effects. At 800 mg, the likelihood of 30% excess toxicity over controls was estimated to be 0.9%. Patients who were given the drug experienced a variety of side effects, including palpitations, impaired vision, stomach difficulties, weariness, infections, chest wall pain, nervous system abnormalities, cough and bilateral thigh pain.

A phase 2 trial with 800 mg molnupiravir can be conducted to study the effect of molnupiravir. ✍

34450619
(J Antimicrob Chemother)

PMID	34450619 Date of Publishing: 2021 Aug 27
Title	Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Author(s) name	Khoo SH, Fitzgerald R et al.
Journal	J Antimicrob Chemother
Impact factor	4.94 Citation count: 16
Date of Entry	2021 Oct 30

NLM format

Among all treatment group patients, Lopinavir/ritonavir group patients experienced more serious adverse effects (52.8% in the lopinavir/ritonavir group vs. 38.5% in the control group; 54.2% in the lopinavir/ritonavir plus IFN-�-1a group vs. 38.5% in the control group). 44.1% of patients in the Hydroxychloroquine treated group had Serious adverse effects.

4 non-pulmonary-related deaths were found in two treatment groups (lopinavir/ritonavir group, n=1; lopinavir/ritonavir plus IFN-�-1a group, n=3). ✍

Pre-print (medRXiv)

Title	Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
Author(s) name	-
Impact factor	N/A
Date of Entry	2021 Jun 14

The case study is of a 66-year-old man who experienced acute colic perforation after being treated with tocilizumab and corticosteroids for his COVID-19 diagnosis.

The patient had a medical history of metabolic syndrome without any regular treatment. ✍

32402416
(Cir Esp (Engl Ed))

PMID	32402416 Date of Publishing: 2021 Feb
Title	Intestinal perforation in patient with COVID-19 infection treated with tocilizumab and corticosteroids. Report of a clinical case
Author(s) name	Gonzálvez Guardiola P, Díez Ares JÁ et al.
Journal	Cir Esp (Engl Ed)
Impact factor	1.2 Citation count: 10

NLM format
Gonzálvez Guardiola P, Díez Ares JÁ, Peris Tomás N, Sebastián Tomás JC, Navarro Martínez S. Intestinal perforation in patient with COVID-19 infection treated with tocilizumab and corticosteroids. Report of a clinical case. Cir Esp (Engl Ed). 2021 Feb;99(2):156-157. PMID:32402416

Compared to the placebo group patients, the fluvoxamine-treated group patients showed less serious adverse effects.

✍

33180097
(JAMA)

PMID	33180097 Date of Publishing: 2020 Dec 8
Title	Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
Author(s) name	Lenze EJ, Mattar C et al.
Journal	JAMA
Impact factor	14.78 Citation count: 151

NLM format
Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19 . JAMA. 2020 Dec 8;324(22):2292-2300. PMID:33180097

Several common serious adverse effects were observed between two groups of patients (IFX-1 and control). In the IFX-1 group, 23 serious adverse effects occurred in 9 out of 15 patients. In the control group, 19 adverse effects occurred in 7 out of 15 patients.

✍

33015643
(Lancet Rheumatol)

PMID	33015643 Date of Publishing: 2020 Dec
Title	Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Author(s) name	Vlaar APJ, de Bruin S et al.
Journal	Lancet Rheumatol
Impact factor	- n/a - Citation count: 69

NLM format

Vlaar APJ, de Bruin S, Busch M, Timmermans SAMEG, van Zeggeren IE, Koning R, Ter Horst L, Bulle EB, van Baarle FEHP, van de Poll MCG, Kemper EM, van der Horst ICC, Schultz MJ, Horn J, Paulus F, Bos LD, Wiersinga WJ, Witzenrath M, Rueckinger S, Pilz K, Brouwer MC, Guo RF, Heunks L, van Paassen P, Riedemann NC, van de Beek D. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol. 2020 Dec;2(12):e764-e773. PMID:33015643

A significant increase in Aminotransferase levels was observed in patients treated with Tocilizumab (TCZ), compared to Anakinra (ANA) treated group patients.

Anakinra can be used to treat COVID-19 patients elevated aminotransferases and also useful for patients who do not respond to TCZ. ✍

32843231
(J Autoimmun)

PMID	32843231 Date of Publishing: 2020 Dec
Title	High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients
Author(s) name	Iglesias-Julián E, López-Veloso M et al.
Journal	J Autoimmun
Impact factor	7.32 Citation count: 23

NLM format

Iglesias-Julián E, López-Veloso M, de-la-Torre-Ferrera N, Barraza-Vengoechea JC, Delgado-López PD, Colazo-Burlato M, Ubeira-Iglesias M, Montero-Baladía M, Lorenzo-Martín A, Minguito-de-la-Iglesia J, García-Muñoz JP, Sanllorente-Sebastián R, Vicente-González B, Alemán-Alemán A, Buzón-Martín L. High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients . J Autoimmun. 2020 Dec;115:102537. PMID:32843231

Adverse effects were similar between two groups (Remdesivir and placebo) of patients. Serious adverse effects were reported in 131 patients in the Remdesivir group and 163 patients in the placebo group.

✍

32445440
(N Engl J Med)

PMID	32445440 Date of Publishing: 2020 Nov 5
Title	Remdesivir for the Treatment of Covid-19 Final Report
Author(s) name	Beigel JH, Tomashek KM et al.
Journal	N Engl J Med
Impact factor	37.91 Citation count: 2581

NLM format

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 Final Report. N Engl J Med. 2020 Nov 5;383(19):1813-1826. PMID:32445440

The patient treated with Remedesivir experienced acute liver failure which improved with the treatment of acetylcysteine

The patient had a medical history of hypertension, diabetes mellitus, hyperlipidemia, and coronary artery disease (CAD) ✍

33006138
(Pharmacotherapy)

PMID	33006138 Date of Publishing: 2020 Nov
Title	Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series
Author(s) name	Carothers C, Birrer K, Vo M.
Journal	Pharmacotherapy
Impact factor	3.17 Citation count: 19

NLM format
Carothers C, Birrer K, Vo M. Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series. Pharmacotherapy. 2020 Nov;40(11):1166-1171. PMID:33006138

The patient treated with Remedesivir experienced acute liver failure which improved with the treatment of acetylcysteine

The patient had a medical history of hypertension, diabetes mellitus, and hyperlipidemia. ✍

33006138
(Pharmacotherapy)

PMID	33006138 Date of Publishing: 2020 Nov
Title	Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series
Author(s) name	Carothers C, Birrer K, Vo M.
Journal	Pharmacotherapy
Impact factor	3.17 Citation count: 19

NLM format
Carothers C, Birrer K, Vo M. Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series. Pharmacotherapy. 2020 Nov;40(11):1166-1171. PMID:33006138

Patients with adverse effects were more in the HCQ group than the placebo group. The most common adverse effects were stomach upset, nausea, abdominal pain, diarrhea, or vomiting.

No serious adverse effects were reported. ✍

32673060
(Ann Intern Med)

PMID	32673060 Date of Publishing: 2020 Oct 20
Title	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 A Randomized Trial
Author(s) name	Skipper CP, Pastick KA et al.
Journal	Ann Intern Med
Impact factor	11.75 Citation count: 241

NLM format

Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, Williams DA, Okafor EC, Pullen MF, Nicol MR, Nascene AA, Hullsiek KH, Cheng MP, Luke D, Lother SA, MacKenzie LJ, Drobot G, Kelly LE, Schwartz IS, Zarychanski R, McDonald EG, Lee TC, Rajasingham R, Boulware DR. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 A Randomized Trial. Ann Intern Med. 2020 Oct 20;173(8):623-631. PMID:32673060

Adverse effects were common between treatment groups (hydroxychloroquine and control group). The most common adverse effects were gastrointestinal discomfort, diarrhea, headache, nausea, or dizziness. Few serious adverse events were also reported.

✍

33082342
(Nat Commun)

PMID	33082342 Date of Publishing: 2020 Oct 20
Title	A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics
Author(s) name	Lyngbakken MN, Berdal JE et al.
Journal	Nat Commun
Impact factor	11.8 Citation count: 41

NLM format
Lyngbakken MN, Berdal JE, Eskesen A, Kvale D, Olsen IC, Rueegg CS, Rangberg A, Jonassen CM, Omland T, Røsjø H, Dalgard O. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. Nat Commun. 2020 Oct 20;11(1):5284. PMID:33082342

Out of 25 patients treated with Tocilizumab, 23 experienced at least one adverse event. Anemia, alanine aminotransferase (ALT) rise, and QT interval prolongation were the most frequent adverse events.

The median age of patients was 58 years (interquartile range, 50-63). Co-morbidities included diabetes mellitus, chronic kidney diseases, and cardiovascular disease. ✍

32369191
(J Med Virol)

PMID	32369191 Date of Publishing: 2020 Oct
Title	Tocilizumab for the treatment of severe coronavirus disease 2019
Author(s) name	Alattar R, Ibrahim TBH et al.
Journal	J Med Virol
Impact factor	2.07 Citation count: 127

NLM format
Alattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K, Daghfal JN, Khatib MY, Aboukamar M, Abukhattab M, Alsoub HA, Almaslamani MA, Omrani AS. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. 2020 Oct;92(10):2042-2049. PMID:32369191

3 out of 4 patients, was observed to have serious adverse events.

Patient 3 died due to multiple organ failures ✍

32418190
(Infection)

PMID	32418190 Date of Publishing: 2020 Oct
Title	Early experience with remdesivir in SARS-CoV-2 pneumonia
Author(s) name	Durante-Mangoni E, Andini R et al.
Journal	Infection
Impact factor	2.84 Citation count: 13

NLM format
Durante-Mangoni E, Andini R, Bertolino L, Mele F, Florio LL, Murino P, Corcione A, Zampino R. Early experience with remdesivir in SARS-CoV-2 pneumonia. Infection. 2020 Oct;48(5):779-782. PMID:32418190

This observational study is based on an algorithm that was structured to use tocilizumab for the treatment of COVID-19 patients with Cytokine Release Syndrome. Following tocilizumab treatment, oxygenation and inflammatory biomarkers improved. And D-dimer and soluble IL-2 receptor levels increased significantly.

✍

32553536
(Chest)

PMID	32553536 Date of Publishing: 2020 Oct
Title	Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes
Author(s) name	Price CC, Altice FL et al.
Journal	Chest
Impact factor	7.22 Citation count: 102

NLM format

Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes. Chest. 2020 Oct;158(4):1397-1408. PMID:32553536

4 Out of 5 patients treated with Remdesivir showed side effects.

Age of case 1: 31-year-old. Age of case 2: 80-year-old Age of case 3: 39-year-old Age of case 4: 76-year-old Age of case 5: 70-year-old ✍

32619764
(Int J Infect Dis)

PMID	32619764 Date of Publishing: 2020 Sep
Title	Case report study of the first five COVID-19 patients treated with remdesivir in France
Author(s) name	Dubert M, Visseaux B et al.
Journal	Int J Infect Dis
Impact factor	3.42 Citation count: 14

NLM format
Dubert M, Visseaux B, Isernia V, Bouadma L, Deconinck L, Patrier J, Wicky PH, Le Pluart D, Kramer L, Rioux C, Le Hingrat Q, Houhou-Fidouh N, Yazdanpanah Y, Ghosn J, Lescure FX. Case report study of the first five COVID-19 patients treated with remdesivir in France. Int J Infect Dis. 2020 Sep;98:290-293. PMID:32619764

Side effects were more common in patients treated with hydroxychloroquine than with placebo. The most common side effects were nausea, loose stools, and abdominal discomfort.

✍

32492293
(N Engl J Med)

PMID	32492293 Date of Publishing: 2020 Aug 6
Title	A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
Author(s) name	Boulware DR, Pullen MF et al.
Journal	N Engl J Med
Impact factor	37.91 Citation count: 601

NLM format

Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, Skipper CP, Nascene AA, Nicol MR, Abassi M, Engen NW, Cheng MP, LaBar D, Lother SA, MacKenzie LJ, Drobot G, Marten N, Zarychanski R, Kelly LE, Schwartz IS, McDonald EG, Rajasingham R, Lee TC, Hullsiek KH. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020 Aug 6;383(6):517-525. PMID:32492293

Of 52 convalescent plasma-treated patients, 2 experienced adverse effects within an hour of transfusion. The observed adverse effects were Chills, rashes, shortness of breath, cyanosis, and severe dyspnea.

✍

32492084
(JAMA)

PMID	32492084 Date of Publishing: 2020 Aug 4
Title	Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19
Author(s) name	Li L, Zhang W et al.
Journal	JAMA
Impact factor	14.78 Citation count: 647

NLM format

Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, Kong Y, Ren L, Wei Q, Mei H, Hu C, Tao C, Yang R, Wang J, Yu Y, Guo Y, Wu X, Xu Z, Zeng L, Xiong N, Chen L, Wang J, Man N, Liu Y, Xu H, Deng E, Zhang X, Li C, Wang C, Su S, Zhang L, Wang J, Wu Y, Liu Z. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19. JAMA. 2020 Aug 4;324(5):460-470. PMID:32492084

In this multi-center observational study, severe COVID-19 patients were treated with hyperimmune plasma therapy to reduce mortality. After transfusions, five serious adverse events occurred in four patients.

✍

33256382
(Haematologica)

PMID	33256382 Date of Publishing: 2020 Jul 23
Title	Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial
Author(s) name	Perotti C, Baldanti F et al.
Journal	Haematologica
Impact factor	7.53 Citation count: 76

NLM format

Perotti C, Baldanti F, Bruno R, Del Fante C, Seminari E, Casari S, Percivalle E, Glingani C, Musella V, Belliato M, Garuti M, Meloni F, Frigato M, Di Sabatino A, Klersy C, De Donno G, Franchini M, Covid-Plasma Task Force. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica. 2020 Dec 1;105(12):2834-2840. PMID:33256382

The group of patients treated with only HCQ or HCQ + Azithromycin showed more serious adverse events (like Cardiac arrest, arrhythmia, and QT prolongation) compared to patients who did not receive any drug.

✍

32392282
(JAMA)

PMID	32392282 Date of Publishing: 2020 Jun 23
Title	Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Author(s) name	Rosenberg ES, Dufort EM et al.
Journal	JAMA
Impact factor	14.78 Citation count: 578

NLM format
Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, Weinberg P, Kirkwood J, Muse A, DeHovitz J, Blog DS, Hutton B, Holtgrave DR, Zucker HA. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. 2020 Jun 23;323(24):2493-2502. PMID:32392282

This study compares the effect of convalescent plasma therapy against the control group on viral shedding and survival in COVID-19 patients with serious respiratory failure.

The study recommends the convalescent plasma therapy to potentially critical COVID-19 patients at their early phase of infection for better results ✍

32348485
(J Infect Dis)

PMID	32348485 Date of Publishing: 2020 Jun 16
Title	Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019
Author(s) name	Zeng QL, Yu ZJ et al.
Journal	J Infect Dis
Impact factor	4.73 Citation count: 176

NLM format
Zeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang GF, Xu JH, Lin WB, Cui GL, Zhang MM, Li C, Wang ZS, Zhang ZH, Liu ZS. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019. J Infect Dis. 2020 Jun 16;222(1):38-43. PMID:32348485